Author:
Alcolea Pedro J.,Larraga Jaime,Rodríguez-Martín Daniel,Alonso Ana,Loayza Francisco J.,Rojas José M.,Ruiz-García Silvia,Louloudes-Lázaro Andrés,Carlón Ana B.,Sánchez-Cordón Pedro J.,Nogales-Altozano Pablo,Redondo Natalia,Manzano Miguel,Lozano Daniel,Palomero Jesús,Montoya María,Vallet-Regí María,Martín Verónica,Sevilla Noemí,Larraga Vicente
Abstract
SARS-CoV-2 vaccines currently in use have contributed to controlling the COVID-19 pandemic. Notwithstanding, the high mutation rate, fundamentally in the spike glycoprotein (S), is causing the emergence of new variants. Solely utilizing this antigen is a drawback that may reduce the efficacy of these vaccines. Herein we present a DNA vaccine candidate that contains the genes encoding the S and the nucleocapsid (N) proteins implemented into the non-replicative mammalian expression plasmid vector, pPAL. This plasmid lacks antibiotic resistance genes and contains an alternative selectable marker for production. The S gene sequence was modified to avoid furin cleavage (Sfs). Potent humoral and cellular immune responses were observed in C57BL/6J mice vaccinated with pPAL-Sfs + pPAL-N following a prime/boost regimen by the intramuscular route applying in vivo electroporation. The immunogen fully protected K18-hACE2 mice against a lethal dose (105 PFU) of SARS-CoV-2. Viral replication was completely controlled in the lungs, brain, and heart of vaccinated mice. Therefore, pPAL-Sfs + pPAL-N is a promising DNA vaccine candidate for protection from COVID-19.
Funder
Consejo Superior de Investigaciones Científicas
Centro para el Desarrollo Tecnológico Industrial
Comunidad de Madrid
European Research Council
Subject
Immunology,Immunology and Allergy
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献